GlassScriptPhysician profile
Jade W Kimble
NPI 1689281958
$5,793.97
in general payments reported to CMS, 2019-2025
33 companies · $1,818 in 2025
The $1,818 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $327 · 2022: $1,208 · 2023: $1,354 · 2024: $1,087 · 2025: $1,818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,175 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,175.06 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,332.08 | 2021-2025 | |
| Janssen Biotech, INC. | $605.87 | 2021-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $536.64 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $509.32 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $431.07 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Qol Medical, LLC | $232.84 | 2021-2025 | Sucraid |
| Alnylam Pharmaceuticals INC. | $212.99 | 2022-2025 | Givlaari |
| Phathom Pharmaceuticals, INC. | $209.92 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $168.60 | 2021-2023 | |
| Lilly USA, LLC | $153.39 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $137.04 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $136.83 | 2023-2025 | Dupixent |
| Genzyme Corporation | $133.66 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $126.98 | 2024-2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $123.12 | 2022-2025 | Rebyota |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $100.87 | 2025 | Rezdiffra |
| Redhill Biopharma INC. | $92.50 | 2021-2022 | |
| Daiichi Sankyo INC. | $83.62 | 2022 | |
| Intercept Pharmaceuticals, INC. | $65.07 | 2021-2024 | |
| Organon LLC | $55.33 | 2023-2025 | Hadlima |
| Novo Nordisk INC | $45.60 | 2024-2025 | Wegovy |
| Braintree Laboratories, INC. | $43.86 | 2023-2025 | Suflave, Sutab |
| Pfizer INC. | $43.65 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $41.08 | 2024 | |
| Amgen INC. | $33.12 | 2023 | Avsola, Amjevita |
| Merck Sharp & Dohme LLC | $29.50 | 2021-2023 | Dificid |
| Sandoz INC. | $21.76 | 2024 | Hyrimoz |
| Evoke Pharma, INC. | $21.65 | 2022 | |
| Vivus LLC | $17.99 | 2025 | Pancreaze |
| Ethicon US, LLC | $14.20 | 2021 | |
| Celgene Corporation | $13.95 | 2024 | Zeposia |
| Shield Therapeutics INC | $12.77 | 2023 | Accrufer |
| Intra-Sana Laboratories | $7.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jade Kimble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.